#mentorship is a mutual relationship. So proud of you Sergio Facchini

New study from Italy highlights an important gap in conducting clinical trials—cancer patients enrolled in clinical trials only partially represent those who have been treated in clinical practice. #Oncology #RCTs Francesco Perrone Massimo Di Maio Maria Lucia Iacovino tinyurl.com/bdfs7rkj

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy. Read the full CheckMate 8HW trial results: nej.md/4eGp1tj

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic #ColorectalCancer: The IMPROVE Trial. brnw.ch/21wP57u

FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for mCRC with mBRAF V600E 👉BREAKWATER phs-3 👉 ORR 61% vs 40% 👉mDoR 13.9 vs 11.1 mo 👉Evaluation of PFS & OS ongoing ESMO - Eur. Oncology

ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma esmoopen.com/article/S2059-…

Proud to announce the creation of the European Interdisciplinary Society for AI in Cancer Research EU Interdisc. Society of AI for Cancer Research is here to advance AI focus on the multidisciplinarity necessary to, effectively implement AI in Cancer Research stellar Steering Committee ! #AIinCancer Jakob Nikolas Kather

DESTINY-Gastric04 trial shows trastuzumab deruxtecan significantly improves overall survival in 2L HER2+ metastatic gastric cancer vs. standard chemo. OncoAlert daiichisankyo.us/press-releases…

💊Final OS analysis of CodeBreak-300 Journal of Clinical Oncology ➡️Sotorasib 960 + panitumumab vs. inv. choice ✅ORR: 30.2% vs 1.9% ✅mPFS: 5.6 vs 2 mo. HR: 0.48 (0.30-0.78), p=.005 ❓mOS: Not reached vs. 10.3 mo HR: 0.70 (0.41 to 1.18), p=.20 👉doi.org/10.1200/JCO-24… OncoAlert ONCO BRUNO

🔥Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up🔥 Annals of Oncology doi.org/10.1016/j.anno… 👉Important updates on the treatment of rectal cancer 👉Multiple options and strategies ESMO - Eur. Oncology

#ASCO25 NEJM BREAKWATER: Encorafenib + cetuximab + mFOLFOX6 vs standard care in 1L BRAF V600E mCRC PFS➡️12.8 vs 7.1 mo✅️ OS➡️ 30.3 vs 15.1 mo✅️👏 💥For one of the hardest-to-treat mCRC subtypes, this triplet shows substantial survival benefit. nejm.org/doi/full/10.10…

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

📢🟠ATOMIC #ASCO25 ➡️Adj atezolizumab + FOLFOX vs FOLFOX in stage III dMMR colon ca ✅3-y DFS: 86.4% vs 76.6% HR: 0.50, P<0.0001 OncoAlert ASCO #cancer #oncology #MedX #colon

Proposed changes to the pathologic staging for colon cancer (CC): AJCC Colon Cancer Expert Panel (AJCCCCEP) #ASCO25 👉Enhanced prognostic prediction 👉Robust validation ESMO - Eur. Oncology

🔥Plenary Discussion of LBA5🔥 📷 #ASCO2025 👏Great discussion by Sam Klempner 👉D-FLOT reached it's primary endpoint and will change clinical practice 👉More to come: from MATTERHORN to EVEREST ESMO - Eur. Oncology

x.com/i/article/1929…

MATTERHORN: Phase III study of durvalumab + FLOT in resectable G / GEJ adenocarcinoma #ESMO25 #ESMOAmbassadors 👉 pCR: 16%, MPR: 26%, any: 87% 👉 OS: HR: 0.78; 36-mo OS: 68 vs 61% 🧐OS improved independent of TAP, better in responders > new SOC @myesmo